Skip to main content

Evolva brings natural sugar blocker to market

| News

Evolva brings natural sugar blocker to market


The biotech company Evolva is introducing L-arabinose to the market. This product is a natural sugar blocker and can be used both for healthy eating and as a reducing sugar in food processing.

Research and development in a laboratory of Evolva (img: Evolva)

Evolva, a biotech company headquartered in Reinach in the canton of Basel-Landschaft, has presented its new product L-arabinose, a natural sugar blocker. According to a press release, studies have demonstrated the effect of L-arabinose on adjusting to a healthy blood sugar level. The sugar blocker can also help with maintaining a healthy weight, for example by foregoing food and drink that contains a lot of sugar. L-arabinose is created by fermentation and is a good substitute for sugar in products such as yogurt, chocolate, soft drinks, ice cream, cereals, energy bars, and confectionary. The company’s press release states that its effect as a reducing sugar means that it can be used to create salty and savory chicken and beef flavors.

Oliver Walker, CEO of Evolva, is quoted as saying: “As people around the world continue to strive to live a healthier lifestyle, we are committed to helping our customers create healthier, more sustainable solutions. With this launch we are confirming our ability to deliver innovations that support human health and wellbeing.”

This new, natural sugar blocker is also of economic interest. Evolva has a current market volume of 250 million Swiss francs, and market growth of around 5 percent per year is anticipated. Evolva has revealed that marketing discussions are already underway with major clients.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

biGENIUS receives 2 million euros for new cloud product

Software company biGENIUS, based in the Basel Area, has secured financing of 2 million euros. This funding was granted following...
Read More

Opterion Health secures investment of 6.5 million Swiss francs

Opterion Health has raised a total of 6.5 million Swiss francs as part of a financing round. The company, which...
Read More

TOLREMO receives 39 million US dollars in investments

TOLREMO Therapeutics has concluded a series A funding round with 39 million US dollars. The biotech company based in Basel...
Read More

Mazars opens tenth Swiss office in Basel

Mazars is now also present in Basel with a subsidiary as of September 1. This is the tenth Swiss location...
Read More

Medtech in Switzerland – bringing together traditional skills and hightech industry

How the intersection of traditional and novel skillsets in the Jura area is propelling Switzerland into a new era of...
Read More

Fondation Botnar supporting further research into pediatric health

The Basel-based Botnar Research Centre for Child Health has received a further donation of 50 million Swiss francs from the...
Read More

Do you have a question? We'd like to hear from you.